Lylana Transdermal Patch Substitution
I cannot provide a specific NDC code to substitute for Lylana patches because the evidence provided does not contain information about Lylana's formulation, active ingredients, or approved therapeutic equivalents.
Critical Information Gap
The only reference to "Lylana" in the evidence 1 appears to be a data error or mislabeling (it mentions "TD Gold Voice Blood Glucose Monitor"), which is completely unrelated to transdermal hormone patches. Without knowing:
- What active ingredient(s) Lylana contains (estradiol alone, estradiol + progestin combination, etc.)
- The specific dosage (e.g., 50 μg/day, 100 μg/day)
- Whether it's a combined or estrogen-only patch
- The approved indication (contraception, hormone replacement, etc.)
...it is impossible to recommend an appropriate therapeutic substitute.
How to Find an Acceptable Substitute
To identify an appropriate NDC for substitution, you must:
Verify Lylana's active ingredients and strength from the actual product labeling or prescribing information
Determine therapeutic equivalence using the FDA's Orange Book or contact the manufacturer
Match the formulation type:
Consult your pharmacy system for AB-rated generic equivalents with valid, representative NDC numbers (not obsolete, repackaged, or private label codes) 3
Common Pitfalls
- Using non-representative NDC codes (obsolete, repackaged, unit dose, or private label) creates workflow disruptions and potential dispensing errors 3
- Approximately 1 in 500 e-prescriptions contain NDC numbers pointing to completely different drug concepts than intended 3
- Always verify that the NDC description matches the intended drug formulation before dispensing
Contact the prescriber directly to clarify the intended active ingredient, strength, and therapeutic indication before attempting substitution.